FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income(1) of $161 Million, Representing 35% Year-Over-Year Growth FY 2025 Adjusted EBITDA(2) of $231 Million, Representing 40% Year-Over-Year Growth Incoming CFO Appointment Expected to Further Enhance Financial Strategy, Working Capital Execution and Capital Allocation Discipline Advancing SG-001 Pipeline Program with Anticip ...

Core Insights - CBIZ, Inc. reported a significant increase in full-year revenue by 52% to $2.76 billion and a 135% rise in earnings per share (EPS) to $1.83, driven by the acquisition and nearly complete integration of Marcum [1][7][27] - The company anticipates continued growth in 2026, projecting revenue between $2.8 billion and $2.9 billion, adjusted EPS of approximately $3.75 to $3.85, and free cash flow of $270 million to $290 million [5][9] Financial Performance - Full-year revenue reached $2.76 billion, up 52.1% from the previous year, with net income increasing by 181.3% to $115.4 million [7][27] - Adjusted EBITDA for the year was $446.9 million, reflecting a 125.5% increase, while operating cash flow rose by 55.6% to $192.5 million [7][28] - Free cash flow improved by 58.4% to $175.5 million, with a share repurchase of 2.5 million shares for $168 million [7][8] Strategic Initiatives - The company has focused on integrating Marcum, standardizing tools and processes, and forming industry groups to offer tailored solutions [3][8] - Key strategic priorities for 2026 include attracting top talent, enhancing the national brand, leading with industry specialization, and delivering value through expanded services [3][8] - CBIZ has successfully created over 200 million branding impressions and generated over 50,000 new leads through its national brand campaign [8] Market Position and Outlook - The company is positioned to leverage its scale and investments in offshoring, AI, and innovation to transform its cost structure and drive growth [3][8] - The 2026 outlook suggests low to mid-single-digit revenue growth, improved profitability, and strong free cash flow conversion [9][5] - CBIZ has been recognized as the 1 construction accounting firm, indicating a strong market position in its industry [8]

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- At the end of the settlement date of February 13, 2026, short interest in 3,595 Nasdaq Global MarketSM securities totaled 15,834,216,597 shares compared with 15,574,683,465 shares in 3,547 Global Market issues reported for the prior settlement date of January 30, 2026. The mid-January short interest represents 2.25 days compared with 2.58 days for the prior reporting period. Short interest in 1,654 securities on The Nasdaq Capital MarketSM totaled 3,724,995,849 sh ...

FOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be participating in the following upcoming investor conferences in March. TD Cowen's 46th Annual Health Care ConferenceFormat: Fireside ChatDate and Time: Monday, March 2, 2026 at 3:50 p.m. ET Location: Boston, MA Leerink Global Healthcare Conference Format: Fireside ChatDate and Time: Monday, M ...

Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid antibody for Alzheimer’s Disease), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson’s Disease) and AL064 (ABC-enabled Tau siRNA for Alzheimer’s Disease) Independent interim futility analysis of the PROGRESS-AD Phase 2 trial of nivisnebart (AL101) in early Alzheimer’s disease expected in the first h ...

Core Insights - Ormat Technologies, Inc. reported strong financial performance for the fourth quarter and full year ended December 31, 2025, with total revenues increasing by 12.5% year-over-year to nearly $1 billion, driven by growth in the Energy Storage and Product segments [5][6][8] - The company signed long-term Power Purchase Agreements (PPAs) with major clients like Google and Switch, enhancing its revenue growth prospects and supporting its strategic initiatives in geothermal energy [7][8] Financial Performance - Total revenues for Q4 2025 were $276 million, a 19.6% increase from Q4 2024, while full-year revenues reached $989.6 million, up 12.5% from the previous year [3][6] - The Energy Storage segment saw remarkable growth, with revenues increasing by 140.5% in Q4 and 109.3% for the full year [3][8] - The Product segment's revenues surged by 59.1% in Q4 and 55.2% for the full year, attributed to revenue recognition from manufacturing and construction progress [3][8] Profitability Metrics - Gross profit for Q4 2025 was $78.8 million, a 7.2% increase from Q4 2024, while the gross margin for the full year remained stable at 27.6% [3][8] - Net income attributable to the company's stockholders for Q4 was $31.4 million, down 23.2% from the prior year, primarily due to impairment charges [8][30] - Adjusted EBITDA increased by 9.1% in Q4 to $158.7 million and by 5.7% for the full year to $582 million, driven by higher contributions from the Energy Storage segment [3][8] Strategic Developments - The company is advancing next-generation geothermal technologies through partnerships, including a collaboration with SLB to develop Enhanced Geothermal Systems (EGS) [7][8] - Ormat's recent long-term PPAs include a 15-year agreement with Google for up to 150MW and a 20-year agreement with Switch for approximately 13MW, positioning the company for future growth [7][8] Future Outlook - For 2026, Ormat expects total revenues to be between $1,110 million and $1,160 million, with adjusted EBITDA projected to increase to between $615 million and $645 million [8][12] - The company aims to achieve generating capacity goals of 2.6 to 2.8 GW by the end of 2028, supported by favorable market dynamics and regulatory support [7][8]

ALISO VIEJO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter and full year ended December 31, 2025. Strategic Highlights and Recent Developments 2025 Light Adjustable Lens (LAL® and LAL+®) unit sales increased 12% to 109,615Over 300,000 RxSight LAL procedures performed since launch, reinforcing the benefits of post-operative adjustability in clinical practiceLight Delivery Devices (LDD™) installed base expanded to 1,134, providing a str ...

Global portfolio purchases in 2025 up 4% to $1.41 billion, including $1.17 billion in the U.S.Global collections in 2025 up 20% to $2.59 billion, including $1.95 billion in the U.S.Earnings per share in 2025 of $10.91Repurchased approximately 9% of ECPG shares outstanding for $89.5 million in 2025 SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Encore Capital Group, Inc. (NASDAQ: ECPG), an international specialty finance company, today reported consolidated financial results for the fourth quarter and full yea ...

CHIHUAHUA, Mexico, Feb. 25, 2026 (GLOBE NEWSWIRE) -- GCC, S.A.B. de C.V. (BMV: GCC*), a leading company in the production of cement, aggregates and concrete in the United States and Mexico, today announced the acquisition of three companies and their aggregates, asphalt, and ready-mix concrete operations in El Paso, Texas. This transaction strengthens GCC’s growth strategy by incorporating a platform with approximately US$30 million in annual revenues and reinforcing its operational presence in the El Paso, ...

Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was $372.1 million, an increase of 123% over the prior yearReported positive topline data for the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% in children ages 3 to 24 months with mild to moderate atopic dermatitis, with a Supplemental New Drug Application (sNDA) submission expected in Q2 2026Announced expa ...